Jane Street Group LLC Increases Stock Holdings in Artivion, Inc. (NYSE:AORT)

Jane Street Group LLC lifted its stake in shares of Artivion, Inc. (NYSE:AORT) by 69.1% in the third quarter, Holdings Channel reports. The firm owned 61,035 shares of the company’s stock after buying an additional 24,945 shares during the period. Jane Street Group LLC’s holdings in Artivion were worth $1,625,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. nVerses Capital LLC acquired a new stake in Artivion during the 2nd quarter worth $28,000. Quarry LP grew its stake in shares of Artivion by 210.8% in the 3rd quarter. Quarry LP now owns 1,209 shares of the company’s stock valued at $32,000 after buying an additional 820 shares during the period. RiverPark Advisors LLC grew its position in Artivion by 151.6% in the third quarter. RiverPark Advisors LLC now owns 5,387 shares of the company’s stock worth $143,000 after acquiring an additional 3,246 shares during the period. RW Investment Management LLC acquired a new stake in Artivion during the second quarter worth $219,000. Finally, Intech Investment Management LLC acquired a new stake in Artivion during the second quarter worth $253,000. Institutional investors and hedge funds own 86.37% of the company’s stock.

Wall Street Analyst Weigh In

AORT has been the subject of a number of research analyst reports. Stifel Nicolaus increased their price target on Artivion from $28.00 to $30.00 and gave the stock a “buy” rating in a report on Friday, September 13th. Needham & Company LLC reaffirmed a “buy” rating and set a $34.00 target price on shares of Artivion in a research note on Monday, December 9th. JMP Securities reiterated a “market outperform” rating and set a $33.00 price target on shares of Artivion in a research report on Tuesday, December 10th. Finally, Oppenheimer upped their price objective on shares of Artivion from $30.00 to $32.00 and gave the stock an “outperform” rating in a report on Friday, November 8th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $31.80.

Insider Activity at Artivion

In related news, SVP Jean F. Holloway sold 8,070 shares of the stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $30.12, for a total value of $243,068.40. Following the transaction, the senior vice president now owns 153,862 shares of the company’s stock, valued at $4,634,323.44. This represents a 4.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CAO Amy Horton sold 12,430 shares of the firm’s stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $26.18, for a total value of $325,417.40. Following the sale, the chief accounting officer now directly owns 139,989 shares in the company, valued at $3,664,912.02. This trade represents a 8.16 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 32,447 shares of company stock worth $925,424. Corporate insiders own 8.10% of the company’s stock.

Artivion Stock Performance

NYSE AORT opened at $29.34 on Friday. The company has a market cap of $1.23 billion, a P/E ratio of -1,467.00 and a beta of 1.75. Artivion, Inc. has a 1-year low of $16.48 and a 1-year high of $30.45. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.88 and a quick ratio of 1.33. The stock has a 50-day moving average of $28.09 and a two-hundred day moving average of $26.49.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.